SCOTTSDALE, AZ -- (MARKET WIRE) -- March 21, 2007 -- Medistem Laboratories, Inc. (OTCBB: MDSM) (FRANKFURT: S2U) announced today its second pipeline candidate, Tolerostem™, a cellular therapy platform aimed at controlling harmful immunological responses through the use of adult stem cells undergoing a proprietary modification.
